Insights into the pharmacological relevance of lysophospholipid receptors.
Mutoh T, Rivera R, Chun J.
Br J Pharmacol · review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1111/j.1476-5381.2011.01622.x PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fingolimod hydrochloride. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
15 hits[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Winkelmann A, Löbermann M, Reisinger EC, Zettl UK.
Nervenarzt · journal article; english abstract · DOI 10.1007/s00115-011-3360-1A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J, Brinkmann V.
Discov Med · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramuralDevelopment of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y, Milstien S, Spiegel S.
Pharmacol Ther · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.pharmthera.2011.08.004FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.
Valentine WJ, Godwin VI, Osborne DA, Liu J, Fujiwara Y, Van Brocklyn J, Bittman R, Parrill AL, Tigyi G.
J Biol Chem · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m111.263442Delayed fingolimod-associated asystole.
Espinosa PS, Berger JR.
Mult Scler · journal article; case reports · DOI 10.1177/1352458511410344Translational aspects of sphingosine 1-phosphate biology.
Pyne S, Pyne NJ.
Trends Mol Med · review; journal article · DOI 10.1016/j.molmed.2011.03.002Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR, Pearce CJ, Oberlies NH.
J Nat Prod · review; journal article · DOI 10.1021/np2000528Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D.
Mult Scler · research support, non-u.s. gov't; journal article · DOI 10.1177/1352458511400476Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA, Weinstock-Guttman B.
Adv Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s12325-011-0004-6BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution.
Briard E, Orain D, Beerli C, Billich A, Streiff M, Bigaud M, Auberson YP.
ChemMedChem · journal article · DOI 10.1002/cmdc.201000477Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Yoshida Y, Tsuji T, Fujita T, Kohno T.
Biol Pharm Bull · letter; comparative study · DOI 10.1248/bpb.34.933Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.
Dawson G, Qin J.
Biochem Biophys Res Commun · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bbrc.2010.11.115Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S.
Drug Metab Dispos · clinical trial; journal article · DOI 10.1124/dmd.110.035907CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten CJ.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.110.035378